Biomarker panel
Homologous recombination repair gene panel
Homologous recombination repair gene panel is a biomarker panel in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (3), each linked to its source.
Matched identity
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
FDA companion diagnostic
An FDA-cleared or approved companion diagnostic names this biomarker.
Source-level evidence only
Gene-level evidence mining does not apply to this kind of biomarker, so the source assertions on this page are the full depth available for it. A section missing below was not measured, and does not mean zero evidence.
FDA companion diagnostic assertions (3)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| FoundationOne Liquid CDx | Homologous recombination repair (HRR) genes | Foundation Medicine, Inc. | Metastatic Castrate Resistant Prostate cancer (mCRPC) | 2026-05-27 |
| FoundationOne CDx | Homologous recombination repair (HRR) genes | Foundation Medicine, Inc. | Metastatic Castrate Resistant Prostate cancer (mCRPC) | 2026-05-27 |
| FoundationOne CDx | Homologous recombination repair (HRR) genes | Foundation Medicine, Inc. | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | 2020-05-19 |
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and assay-provider ledger.